Drug Landscape ›
Multiple cardiovascular drugs related to "Golden Triangle" ›
Regulatory · United States
Marketing authorisations
FDA — authorised 7 June 2010
Application: ANDA065496
Marketing authorisation holder: ALKEM LABS LTD
Status: supplemented
FDA — authorised 10 June 2010
Application: ANDA090314
Marketing authorisation holder: ONESOURCE SPECIALTY
Status: approved
FDA — authorised 28 July 2017
Application: ANDA205327
Marketing authorisation holder: OSMOTICA PHARM US
Status: approved
FDA — authorised 4 September 2019
Application: ANDA208058
Marketing authorisation holder: HERITAGE PHARMA AVET
Status: approved
FDA — authorised 10 December 2020
Application: ANDA212977
Marketing authorisation holder: XIROMED
Status: supplemented
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 368,556
Most-reported reactions
Nausea — 44,902 reports (12.18%) Fatigue — 43,214 reports (11.73%) Pain — 41,550 reports (11.27%) Drug Ineffective — 40,675 reports (11.04%) Diarrhoea — 37,470 reports (10.17%) Drug Dependence — 35,334 reports (9.59%) Dyspnoea — 32,797 reports (8.9%) Off Label Use — 31,709 reports (8.6%) Headache — 31,368 reports (8.51%) Vomiting — 29,537 reports (8.01%)
Source database →
Multiple cardiovascular drugs related to "Golden Triangle" in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Multiple cardiovascular drugs related to "Golden Triangle" approved in United States?
Yes. FDA authorised it on 7 June 2010; FDA authorised it on 10 June 2010; FDA authorised it on 28 July 2017.
Who is the marketing authorisation holder for Multiple cardiovascular drugs related to "Golden Triangle" in United States?
ALKEM LABS LTD holds the US marketing authorisation.